- Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
- Interventions
- Autologous HB-adMSCs
- Drug
- Lead sponsor
- Hope Biosciences Research Foundation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 103
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Dimethyl Fumarate
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Seattle, Washington
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
- Interventions
- BIIB033, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Centennial, Colorado
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- 3 mg Melatonin, 5 mg Melatonin
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Interventions
- Not listed
- Lead sponsor
- LAPIX Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Chevy Chase, Maryland • New York, New York + 1 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- abatacept, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 20
- States / cities
- Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more
- Conditions
- Multiple Sclerosis
- Interventions
- Betaseron, Copaxone
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Multiple Sclerosis (MS) Relapsing Remitting
- Interventions
- Powered Hip Flexion Orthosis (Hypershell X)
- Device
- Lead sponsor
- University of Dayton
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Multiple Sclerosis
- Interventions
- Betaseron (Interferon beta-1b, BAY86-5046)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 3 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapse Remitting Multiple Sclerosis
- Interventions
- Ofatumumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 31 more
- Conditions
- Multiple Sclerosis
- Interventions
- ELND002, Placebo
- Drug
- Lead sponsor
- Elan Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 17
- States / cities
- Berkeley, California • Fresno, California • Newport Beach, California + 14 more
- Conditions
- Multiple Sclerosis
- Interventions
- Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate)
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Interventions
- Remibrutinib (Open Label)
- Drug
- Lead sponsor
- Moein Amin
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Sclerosis
- Interventions
- HB-adMSCs, Placebo
- Biological · Drug
- Lead sponsor
- Hope Biosciences Research Foundation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
- Conditions
- Multiple Sclerosis, RRMS, Relapsing Remitting MS
- Interventions
- HP 13C pyruvate injection, MRI Scanner
- Drug · Device
- Lead sponsor
- Ari Green
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
- Drug · Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
- Conditions
- Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
- Interventions
- Caprylic Triglyceride, Placebo
- Dietary Supplement
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Multiple Sclerosis
- Interventions
- MSDx Complex-1 Biomarker Test
- Other
- Lead sponsor
- MSDx, Inc.
- Industry
- Eligibility
- 45 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- BG00002 (natalizumab)
- Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
- Conditions
- Multiple Sclerosis
- Interventions
- ALKS 8700
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,057 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 74
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- natalizumab, standard of care
- Drug · Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
- Interventions
- wearable focal vibration therapy
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Gainesville, Florida
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, MS (Multiple Sclerosis), MS, Multiple Sclerosis (MS) Secondary Progressive
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California